^
    Back
    Association details:
    Biomarker:PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JCO Precis Oncol
    Title:

    Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib

    Excerpt:
    Clinically, in an open-label phase II trial, infigratinib demonstrated a confirmed overall response rate (cORR) of 39.3% in FGFR2 fusion-positive cholangiocarcinoma patients who received infigratinib as second-line therapy (Figure 7). Additionally, clinical benefit was observed in...solid tumors tested positive for FGFR fusions.
    DOI:
    10.1200/PO.19.00365